Sunday, June 12, 2016

Concurrent Morning Short Courses

Short Course 2: Principles of In Vitro – In Vivo Extrapolation in the Application of PBPK Modelling
Co-Chairs: Amin Rostami, Certara and University of Manchester, United Kingdom and Young Shin, Chungnam University, Korea
Course Sponsored by Certara and SimulationsPlus

  • Principles in Incorporating IVIVE into PBPK
    Amin Rostami, Certara and University of Manchester, United Kingdom
  • Design and Modeling of IVIVE for Absorption Studies
    Viera Lukacova, Simulations Plus, USA
  • Industrial Applications of PBPK: Where we Were, and Where are we Going?
    Jan Snoeys, Janssen, Belgium
  • IVIVE of Drug Transporters and Addressing Challenges
    Manthena Varma, Pfizer Inc., USA

Short Course 1: ADME Characterization of Biologics and Antibody Drug Conjugates (ADC)
Co-Chairs: Anthony J. Lee, AbbVie, USA and Hea-Young Cho, Cha University, Korea

  • ADME of Biologics
    Edit Tarcsa, AbbVie, USA
  • Screening and ADME Characterization of ADCs
    Young Shin, Chungnam National University, Korea
  • Radiolabeled ADME Studies for Development of ADCs
    Anthony J. Lee, AbbVie, USA
  • Model-based Drug Development of Protein Therapeutics
    Dhaval K. Shah, University at Buffalo, USA

Concurrent Afternoon Short Courses

Short Course 4: Modelling Approaches to the Prediction of Drug-drug Interactions
Co-Chairs: Geoff Tucker, University of Sheffield, United Kingdom and
Hyun-Joo Shim, Donga-ST Research Institute, Korea

  • Introduction
    Geoff Tucker, University of Sheffield, United Kingdom
  • Modelling Methods and Case Studies
    Karen Rowland-Yeo, Certara, United Kingdom
  • Prediction of Drug Interactions at Transporters
    Kazuya Maeda, University of Tokyo, Japan
  • A Scientific View of the Modelling of Complex Drug-drug Interactions
    Shiew-Mei Huang, North Potomac, MD, USA
     

Short Course 3: Drug Induced Liver Injury – How Mechanistic Insights Aid Preclinical Detection and Prediction
Co-Chairs: Yvonne Will, Pfizer, Inc., USA and Sang Ho Lee, Bridge Biotherapeutics Inc., Korea

  • DILI: What is the Problem?
    Gerry Kenna, Drug Safety Consultant, United Kingdom
  • Predicting Toxicities of Reactive Metabolite-Positive Drug Candidates
    Amit Kalgutkar, Pfizer, Inc., USA
  • Expression and Function of Hepatobiliary Transporters are Key Determinants of Drug-induced Hepatotoxicity
    Jose Manautou, University of Connecticut, USA
  • Mitochondrial Toxicity Contributes to Drug Induced Liver Injury
    Yvonne Will, Pfizer, Inc., USA
  • Integrating DILI Hazards Enables Prediction, Assessment, and Management of Human Risk
    Gerry Kenna, Drug Safety Consultant, United Kingdom

Keynote Lecture
Co-Chairs: Jae-Gook Shin, Inje University College of Medicine, Korea and Geoff Tucker, University of Sheffield, United Kingdom

  • Drug Transporters: Starring Roles in New Drug Discovery and Development
    Yuichi Sugiyama, RIKEN, Japan

Monday, June 13, 2016

Plenary Lecture 1
Co-Chairs: Sang-Goo Shin, CHA Health Systems, Korea and Greg Slatter, Acerta Pharma, USA

  • Drug Discovery and Development: Looking for Needles in a Hay Stack
    Marcel Hop, Genentech, USA

Concurrent Symposia

Symposium 2: Redox Modulation of Xenobiotic Metabolism and Toxicity
Co-Chairs: Young-Joon Surh, Seoul National University, Korea and John D. Hayes, University of Dundee, United Kingdom

  • Impact of Keap1-Nrf2 System for Toxicology and Drug Development
    Masayuki Yamamoto, Tohoku University, Japan
  • Reductive Stress Caused by Sustained Activation of the Redox-Sensitive Transcription Factor NRF2: Implications for Cancer Cell Proliferation and Invasiveness
    Young-Joon Surh, Seoul National University, Korea
  • Regulation of Nrf2 by Redox and other Cellular Signalling Pathways, and its Influence on Xenobiotic and Lipid Metabolism
    John D. Hayes, University of Dundee, United Kingdom
  • Redox Regulation of 15-Hydroxyprostaglandin Dehydrogenase Expression
    Hye-Kyung Na, Sungshin Women’s University, Korea

Symposium 1: Disposition of Antibody Drug Conjugates (ADCs): Current Understanding and Challenges
Co-Chairs: Anthony J. Lee, AbbVie, USA and Yong-Bok Lee, Chonnam National University, Korea

  • PBPK Modelling as a Tool to Predict Drug Interactions for ADCs
    Yuan Chen, Genentech, USA
  • Development of Translational PK/PD Models for ADCs
    Dhaval K. Shah, University at Buffalo, USA
  • Current Approaches for ADME Characterization of ADCs: Industry Perspectives
    Edit Tarcsa, AbbVie, USA
  • Development of ADCs: Clinical Pharmacology
    Yow-Ming Wang, USA

Symposium 4: Oncology-focused Modelling and Simulation in Drug R&D
Co-Chairs: Saeho Chong, Enzychem Inc., Korea and Gerald Fetterly, Clinical Pharmacology and Regulatory Affairs at Athenex, USA

  • Introduction
    Saeho Chong, Enzychem Inc. Korea
  • General PK/PD Approach in Oncology
    Gerald Fetterly, Clinical Pharmacology and Regulatory Affairs at Athenex, USA
  •  Translational Projection of the Therapeutic Window in Oncology
    Arijit Chakravarty, Takeda, Japan
  • Combination Therapy is Standard Practice in Oncology: Use of PBPK Modelling for Assessing and Designing DDI Studies
    Rangaraj Narayanan, Celgene, USA
  • Translational Modelling and Simulation for Molecularly-targeted Anticancer Agents to Guide Discovery and Development: The Crizotinib Story
    Shinji Yamazaki, Pfizer, Inc., USA

Symposium 3: Humanized or Transgenic Animal Models in Drug Metabolism and Toxicology Studies
Co-Chairs: Hyunyoung Jeong, University of Illinois at Chicago, USA and
Dong Hwan Kim, Konyang University, Korea

  • Development of Advanced In Vivo Human Liver Models for Medicinal Science
    Hiroshi Suemizu, Central Institute for Experimental Animals Biomedical Research, Japan
  • In Vivo Approaches to Identification of Metabolism-mediated Toxicological Mechanisms
    Xinxin Ding, SUNY Polytechnic Institute, USA
  • The Application of Knock Out and Humanised Models to Study Human Pathways of Anti-cancer Drug Metabolism
    A. Kenneth MacLeod, University of Dundee, United Kingdom
  • CYP2D6-humanized Mice as a Model to Study Altered Drug Metabolism During Pregnancy
    Hyunyoung Jeong, University of Illinois at Chicago, USA

Symposium 6: ITC Symposium on Drug Transporters: Best Practice in Drug Development
Co-Chairs: Yuichi Sugiyama, RIKEN, Japan and Shiew-Mei Huang, North Potomac, MD, USA

  • Scientific Perspective on the Evaluation of Transporter-based Drug-drug Interactions
    Shiew-Mei Huang, North Potomac, MD, USA
  • Pharmacogenomics of Membrane Transporters
    Kathy Giacomini, UCSF, USA
  • Exposure or Safety: Where do Transporter Evaluations have the Greater Impact During Drug Development?
    Jasminder Sahi, Sanofi, China
  • Pharmacogenomics and Metabolomics Approaches of OCT Transporter
    Im-Sook Song, Kyungpook National University, Korea

Symposium 5: Emerging Roles of CYP4 Family Enzymes in Endogenous Metabolism and Disease
Co-Chairs: Allan Rettie, University of Washington, USA and Young-Ran Yoon, Kyungpook National University School of Medicine, Korea

  • The CYP4 Family: Overview and Physiological Importance
    Allan Rettie, University of Washington, USA
  • Pharmacogenetics of CYP4 Enzymes: From Discovery to Functional Relevance of Genetic Variants
    Su-Jun Lee, Inje University College of Medicine, Korea
  • The CYP4:20-HETE Pathway in Cancer Progression
    J. Yang, Wuhan University, China
  • CYP4B1 as a Novel Suicide Gene in Cancer Therapy
    Helmut Hanenberg, University of Duisburg-Essen, Germany

 


Tuesday, June 14, 2016

Plenary Lecture 2
Co-Chairs: Jae-Gook Shin, Inje University College of Medicine, Korea and Ichiro Ieiri, Kyushu university, Japan

  • Pharmacogenomics: Relevance to Personalised Medicine
    Munir Pirmohamed, University of Liverpool, United Kingdom

Concurrent Symposia

Symposium 8: Non-HLA Genetic Risk Factors in Idiosyncratic Adverse Drug Reactions
Co-Chairs: Ann Daly, Newcastle University, United Kingdom and In-Jin Jang, Seoul National University College of Medicine and Hospital, Korea

  • Statin-induced Myotoxicity
    Munir Pirmohamed, University of Liverpool, United Kingdom
  • Drug-induced Liver Injury - Recent Findings on Non-HLA Risk Factors
    Ann Daly, Newcastle University, United Kingdom
  • Animal Models to Predict Human Risk Factors in Drug-induced Adverse Drug Reactions
    Tsuyoshi Yokoi, Nagoya University, Japan
  • Pharmacogenomics of Serious Adverse Drug Reactions to Cancer Chemotherapy in Children
    Colin Ross, University of British Columbia, Canada

Symposium 7: The Regulation of Pharmacogenomics in Clinical Drug Development
Co-Chairs: Greg Slatter, Acerta Pharma, USA and Seung Eun Choi, MFDS, Korea

  • Pharmacogenomics in Korea: A Regulatory Perspective
    So Hee Kim, MFDS, Korea
  • Biomarker Regulation and Regulatory Sciences in Japan
    Yoshiro Saito, National Institute of Health Sciences, Ministry of Health, Labour and Welfare, Japan
  • Pharmacogenomics: EU Regulatory Perspective
    Krishna Prasad, MHRA, United Kingdom
  • The Role of Pharmacogenomics in Drug Development, Regulatory Review, and Clinical Practice
    Shiew-Mei Huang, North Potomac, MD, USA

Wednesday, June 15, 2016

Plenary Lecture 3
Co-Chairs: R. Scott Obach, Pfizer, Inc., USA and Chang-Koo Shim, Daewoong Life Science Research Institute, Korea

  • The Role of Toxic Lipids Metabolic Disease
    Frank Gonzalez, National Institutes of Health, USA

Concurrent Symposia

Symposium 10: Pharmaco-metabolomics as Biomarkers for Personalized Medicine
Co-Chairs: Dong Hyun Kim, Inje University College of Medicine, Korea and Thomas Jönsson, Metabolon, Inc., USA

  • Proteo-metabonomics in Elucidating Mechanisms of Acetaminophen Toxicity
    Eric Chun Yong Chan, National University of Singapore, Singapore
  • Global Metabolomics for Precision Medicine: Gain Insights on Gene Penetrance, Early Diagnosis, and Drug Responses
    Thomas Jönsson, Metabolon, Inc., USA
  • Ultrasensitive Metabolomics Techniques for Quantitative Molecular Phenomics
    Huiru Tang, Fudan University, China
  • Pharmacometabolomics for Phenotyping of Hepatic CYP3A Activity and its Application
    Joo Youn Cho, Seoul National University Hospital, Korea

Symposium 9: Proteomic Analysis of Phase 1 and Phase 2 Drug Biotransformation Pathways and Transporters
Co-Chairs: J. Steven Leeder, Children's Mercy Hospitals and Clinics, USA and Sang Geon Kim, Seoul National University, Korea

  • Quantitative Expression of ADME Proteins at the Blood-brain Barrier
    Tetsuya Terasaki, Tohoku University, Japan
  • Quantitative Analysis of Hepatic Transporters and DMEs During Growth and Development
    Bhagwat Prasad, University of Washington, USA
  • Proteomic Assessment of Intestinal Transporters
    Stefan Oswald, Universitatsmedizin Greifswald, Germany
  • Application of Proteomic Analysis of Human CYP Ontogeny:  Creating “Avatars” to Individualize Drug Exposure in Children
    J. Steven Leeder, Children's Mercy Hospitals and Clinics, USA

Symposium 12: Pharmacogenomics for  Personalized Pharmacotherapy: Update on Clinical Implementation
Co-Chairs: Uli Zanger, IKP Stuttgart, Germany and Min Goo Lee, Yonsei University College of Medicine ,Korea

  • Introduction
    Uli Zanger, IKP Stuttgart, Germany
  • Pharmacogenomics of ADME and Personalized Medicine - Where do we stand?
    Matthias Schwab, IKP Stuttgart, Germany
  • Pharmacogenomics of Anticancer Agent Toxicities: Discovery to Implementation
    Eileen Dolan, The University of Chicago, USA
  • Personalized Medicine for Immune Checkpoint Blockades: from Bench to Bedside
    Yijing He, Central South University, China
  • The Implementation of Pharmacogenomics for Personalized Pharmacotherapy in Korea
    Eun-Young Kim, Inje University College of Medicine, Korea

Symposium 11: Analysis and Mechanisms of Disease-related Transporters
Co-Chairs: Ikumi Tamai, Kanazawa University, Japan and Suk-Jae Chung, Seoul National University, Korea

  • A Novel Plasma Membrane Porphyrin Transporter that Affects Porphyria
    John D. Schuetz, St. Jude Children's Research Hospital, USA
  • Cancer Specific Transporters for Diagnosis and Chemotherapy
    Wooin Lee, Seoul National University, Korea
  • Unappreciated Role of Prostaglandin Transporter OATP2A1 in Inflammatory Diseases
    Takeo Nakanishi, Kanazawa Universtiy, Japan
  • Primary Human Proximal Tubule Cell Monolayers as a Predictive Model of Renal Phosphate Homeostasis in Health and Disease
    Colin Brown, Newcastle University, United Kingdom

 


Poster Award Finalist Oral Presentations
Co-Chairs: R. Scott Obach, Pfizer, Inc., USA and Suk-Jae Chung, Seoul National University, Korea

Graduate/Predoctoral Finalists

  • A Highly Selective Near-Infrared Fluorescent Probe For Carboxylesterase 2 and its Bioimaging Applications in Living Systems
    Guang-Bo Ge, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Laboratory of Pharmaceutical Resource Discovery, China
  • Co-Administered Metformin may Increase the Liver Concentration of Atorvastatin by Inhibition Of MRP2 in Rats
    Eunjung Shin, Department of Life and Nanopharmaceutical Science, Kyung Hee University, Korea
  • Protein Abundance and Functional Activity of Clinically Relevant Metabolizing Enzymes along the Human Intestine
    Diana Busch, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald, Germany
  • Metabolic Capability of Upcyte Human Hepatocytes in Long-Term Sandwich Culture and Utility for Clearance Prediction
    Michelle Schaefer, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
  • Comparison of the Inhibitory Effects of Selective Estrogen Receptor Modulators, Tyrosine Kinase Inhibitors, and Steroidal Drugs on Human Aldehyde Oxidase Activity
    Shiyan Chen, National University of Singapore, Singapore
  • PXR Stimulates the Growth Factor-Mediated Hepatocyte Proliferation by Inhibiting FOXO-Mediated Transcription of Cell Cycle Suppressor Genes
    Taiki Abe, Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Japan

Postdoctoral Finalists

  • Pyrrole-Hemoglobin Adduct, a Potential Biomarker of Pyrrolizidine Alkaloid-Induced Hepatotoxicity
    Jiang Ma, The Chinese University of Hong Kong, China
  • Toxicokinetic Study of Pyrrolizidine Alkaloid-Derived DNA Adducts, the Potential Biomarker of Pyrrolizidine Alkaloid-Induced Tumorigenicity
    Lin Zhu, School of Biomedical Sciences, The Chinese University of Hong Kong, China
  • Physiologically-based Pharmacokinetic Predictions of Intestinal BCRP-mediated Effect of Telmisartan on the Pharmacokinetics of Rosuvastatin in Humans
    Soo Hyeon Bae, College of Medicine, The Catholic University of Korea, Korea
  • Characterization of the Intestinal Absorption of Beta-Lactam Antibiotics in a Pept1/Mrp3 Double-Transfected Cell Line And By Using the Ussing Chamber Technique
    Markus Keiser, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald, Germany
  • Multi-Organ-Chip Developments: Towards a Paradigm Shift in Drug Development
    Ilka Maschmeyer, TissUse GmbH, Germany
  • Development of a Physiologically Based Pharmacokinetic Model for Benzyl Butyl Phthalate and its Active Metabolites, Mono Benzyl Phthalate and Mono Butyl Phthalate, in Rats
    Min Gi Kim, Sungkyunkwan University, Korea

Asia-Pacific Regional Session: Xenobiotic Study: Significant Contributions from Asia-Pacific Scientists
Co-Chairs: Wichittra Tassaneeyakul, Khon Kaen University, Thailand and
John Miners, Flinders University, Australia

  • Pharmacogenetics of Drug-induced Severe Cutaneous Adverse Drug Reactions
    Wen-Hung Chung, Chang Gung Memorial Hospital, Taiwan
  • Genetic Markers for Severe Cutaneous Adverse Drug Reactions in Thai Population and their Clinical Status
    Wichittra Tassaneeyakul, Khon Kaen University, Thailand
  • Investigation into the Pharmacokinetics and Pharmacodynamics of Saponins from Panax Notoginseng
    Li Yang, Shanghai University of Traditional Chinese Medicine, China
  • Mechanism-based Biomarkers and the Transformation of Diagnosis and Risk Assessment of Herbal Hepatotoxicity
    Ge Lin, The Chinese University of Hong Kong, Hong Kong
  • Emerging Roles of Human CYP1B1 in Cancer Growth and Metastasis
    Young-Jin Chun, Chung-Ang University, Korea
  • Perspectives of Xenobiotics Science in Asia-Pacific Community: Xenobiotic Metabolism and Transporters - Importance of Translational and Reverse-translation Research
    Yuichi Sugiyama, RIKEN, Japan

Thursday, June 16, 2016

2016 International ISSX Meeting Awards
Chair: Thomas Baillie, University of Washington, USA

  • R.T. Williams Distinguished Scientific Achievement Award
    Presented to Daniel W. Nebeert, M.D., University of Cincinnati Medical Center
  • Frederick J. Di Carlo Distinguished Service Award
    Presented to Nico P.E. Vermeulen, Ph.D., Vrije Universiteit Amsterdam

Concurrent Symposia

Symposium 14: Drug Metabolism in the Era of Precision Medicine
Co-Chairs: Urs A. Meyer, Universitt Basel, Switzerland and Hiroshi Yamazaki, Showa Pharmaceutical University, Japan

  • Introduction
    Urs A. Meyer, Universitt Basel, Switzerland
  • Prediction of Human Pharmacokinetics in Drug Discovery
    Yoichi Naritomi, Astellas Pharma Inc., Japan
  • Challenges for Human Metabolite Prediction in Preclinical
    Takushi Kanazu, Shionogi & Co., Japan
  • Identifying Active Metabolites and Prospectively Predicting their Exposure in Humans
    R. Scott Obach, Pfizer, Inc., USA
  • Human and Monkey P450 Metabolism for Human-specific Metabolite Formation
    Hiroshi Yamazaki, Showa Pharmaceutical University, Japan

Symposium 13: Update on Drug Interaction Studies: from In Silico to Clinical
Co-Chairs: Jasminder Sahi, Sanofi Co., China and Hye Suk Lee, The Catholic University of Korea, Korea

  • The Use of Cynomolgus Monkeys in Predicting Enzyme Induction and Human Drug-drug Interactions
    Michael Sinz, Bristol Myers Squibb, USA
  • Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-drug Interactions
    Odette Fahmi, Pfizer, Inc., USA
  • Pharmacokinetic Herb-Herb and Herb-Drug Interactions: Studies on Fufang-Danshen Formula, a Three-Herb Combination for Management of Angina Pectoris
    Chuan Li, Chinese Academy of Sciences, China
  • Gut Microbiota-mediated Drug-drug Interactions
    Dong-Hyun Kim, Kyung Hee University, Korea

Special Lecture
Chair: Thomas Baillie, University of Washington, USA

  • The Move of PBPK from Academic Nicety to Industrial Necessity
    Amin Rostami, Certara and University of Manchester, United Kingdom







 

Symposium 15: UDP-Glucuronosyltransferase and Drug Glucuronidation
Co-Chairs: John Miners, Flinders University, Australia and Young-Jin Chun, Chung-Ang University, Korea

  • The Inhibition Selectivity of Human UDP-Glucuronosyltransferase Enzymes: Implications for Drug-drug Interactions
    John Miners, Flinders University, Australia
  • UDP-Glucuronosyltransferase Catalyzed Drug Bioactivation: Mechanisms and Potential for Clinically Significant Drug-drug Interactions
    Janne Backman, University of Helsinki, Finland
  • Mutual Modulation of UDP-Glucuronosyltransferases and Cytochrome P450 3A4: Domains Involved in the Functional and Physical Interactions
    Yujii Ishii, Kyushu University, Japan
  • The Regulation of UDP-Glucuronosyltransferase Expression
    Peter Ian Mackenzie, Flinders University, Australia